Key Takeaways
- Revenue crosses INR1,000 crores for the first time, driven by a general medicines recovery, specialty traction, and 11% pediatric vaccine growth.
- EBITDA margin expanded 520 bps to 35.9%, helped by gross margin improvement and cost control, despite a one-off INR11.8 crores labour cost.
- Supply constraints that depressed two quarters are now resolved, with normalization by mid-November/December, setting up a clean Q4.
- Oncology portfolio is live and expanding: first full quarter of Zejula and Jemperli, a haematology team forming, and Blenrep slated for launch next financial year.
- What to watch next quarter: whether the GenMed recovery sustains above-market growth now that supply is fully restored, the pace of oncology patient additions, and any margin giveback as investment in specialty field forces ramps.
General Medicines: The Recovery Quarter
- Return to growth after two soft quarters: GenMed grew 10%, slightly above the ~9% market, as the CMO fire impact that had pulled growth to low single digits normalized by mid-November/December.
- Volume growth turned positive, joining price and new introductions as market drivers; the acute market grew ~8.6% in the quarter.
- Supply losses were real but temporary: products like Calpol and Cobadex CZS were affected for almost three quarters, and some sales were permanently lost even after normalization.
- NLEM overhang is fading: Ceftum, despite a >55% price cut three years ago, is above INR200 crores in value on 3-4% annual volume growth; management expects lower top- and bottom-line impact from NLEM over the next three to five years because most brands are already in-band.
- Underlying growth was higher: management estimates the two soft quarters shaved ~4% off topline growth, meaning underlying growth was at least 4% higher than reported.
Bhushan Akshikar: "I think our ability to therefore hold and deliver consistent performance quarter after quarter is more important than having a flash in the pan."
Specialty & Oncology: Building the Next Growth Engine
- Trelegy Ellipta remains central in triple closed single inhalation therapy, anchoring the respiratory specialty franchise.
- Nucala had a significant quarter, adding ~100 patients per month, signaling accelerating adoption in severe asthma.
- Oncology portfolio is now fully live: Zejula (ovarian cancer) and Jemperli (endometrial cancer) had their first full quarter of availability after an August launch, with a team of 25 key account and product specialists.
- Jemperli's addressable patient pool just expanded ~7.5x: regulatory approval for the RUBY-1 trial in first-line endometrial cancer came in late December, moving the eligible population from ~800 to ~6,000 patients.
- A haematology team is being launched in the coming weeks and months, beginning with multiple myeloma, ahead of Blenrep's expected launch.
- Management declined to give an oncology revenue run rate, calling any estimate a "premature assumption," but emphasized Jemperli's documented overall survival benefit as a differentiator.
Bhushan Akshikar: "It's one of the few or probably the only one, which has got well-articulated and established documented overall survival benefit."
Vaccines: Double-Digit Growth and an Adult Franchise Building
- Pediatric vaccines grew 11%, led by Boostrix, Varilrix, and Havrix, all delivering double-digit growth.
- Shingrix continued gaining market share, supported by a CVMD strategy that is engaging more healthcare organizations and practitioners; management expects volumes to rise further as the financial year closes.
- An RSV adult vaccine trial has been completed, which will complement the adult vaccination space alongside Shingrix, though no launch timeline was given.
Pipeline & Launch Intent: The Five-Year Build
- Blenrep (belantamab) for multiple myeloma: India was part of the global clinical trial; management intends to launch in the coming financial year, probably Q2 or Q3.
- Next-generation ADCs: a compound called B3H7 is slated for trials in India across indications, with at least 12-15 indications targeted over the next five years.
- Bepirovirsen, positioned as the first functional cure for chronic Hepatitis B, had its first global readout in December; India was part of the trial, and management plans to file concurrently with established-market approvals.
- Rule 101 is now in place: marketing authorization in six reference countries should enable simultaneous approval in India, potentially accelerating launch timelines.
- Freshness index ambition: management hazarded a target of 20-25% over five to seven years, with 10-15% targeted for the coming financial year.
- On the risk of the parent bypassing the listed entity: management pointed to Zejula and Jemperli being launched through GSK India as evidence of intent, but did not directly address whether the parent retains the right to launch assets independently in the future.
Bhushan Akshikar: "We have the next generation of ADCs as they're called, antibody drug conjugates. So those are clearly a part of the remit that we have for India."
Margins: Sustaining, Not Expanding
- EBITDA margin reached 35.9%, a 520 bps improvement, driven by gross margin gains, disciplined cost control, and productivity, partially offset by a one-off INR11.8 crores labour cost.
- The stated objective is to hold margins, not expand them: management's first priority is sustaining the margin level delivered over the last three years, using that base to invest in new asset launches and specialty field forces.
- Injectables carry slightly lower margins than the base business due to heavier launch costs, but the base business is large enough that the overall margin profile will not see a material impact.
- Employee cost is expected to grow 7-8% as an inflationary base; a QoQ dip in the quarter reflected prior-year one-off provision reversals, not a structural change.
- Management declined to give forward EBITDA guidance, stating only an "endeavor" to hold margins, and explicitly ruled out targeting further gross margin or EBITDA expansion.
Bhushan Akshikar: "Our objective will be to hold and sustain these margins which we've worked to deliver over the last three years. So that would be the objective rather than expanding gross margin any more or expanding the EBITDA."
Growth Ambition & Market Context
- The five-year target is to double the business: from the FY23-24 base to INR8,000 crores, requiring 12-13% annual growth.
- Profitability is expected to grow broadly in line with revenue over the next three to five years, as the company invests good margin levels into bringing new assets to bolt onto base growth.
- The external market grew ~9% in Q3, with acute at ~8.6%; GSK's GenMed business grew slightly above that after two quarters of underperformance.
- Customs duty reduction on cancer drugs did not benefit GSK: none of its products were included in the budget announcement, and management will make a representation to relevant authorities.
- MIP on amoxicillin had no impact on GSK's margin, EBITDA, or gross margin.
- The model remains "India for India": management confirmed the company is not pursuing a manufacturing-for-export strategy, with exceptions only for national emergencies.
Bhushan Akshikar: "This organization has to grow in the range of 12% to 13% annually over the next five years so that we can double the business from where we were in '23-'24 to the point of becoming an INR8,000 crores business."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Supply normalization | No more supply constraints from the CMO fire impact | From Q4 FY26 onwards |
| Blenrep (belantamab) launch | Launch for multiple myeloma in India | Coming financial year, probably Q2 or Q3 |
| Haematology team launch | Dedicated field force for blood cancers, beginning with multiple myeloma | Coming weeks and months |
| Five-year growth target | 12-13% annual revenue growth to double business to INR8,000 crores | Over five years from FY23-24 base |
| Margin objective | Hold and sustain margins delivered over last three years; no expansion targeted | Ongoing |
| Freshness index | 10-15% target for coming financial year; 20-25% over longer horizon | Coming financial year / 5-7 years |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Standalone revenue | ₹1,000 cr+, +8.1% YoY; first quarter crossing this milestone |
| Consolidated revenue growth | ~10% YoY |
| EBITDA margin | 35.9%, +520 bps YoY; EBITDA growth of 26.7% |
| PAT margin | 27.3%, +290 bps YoY |
| EPS growth | +9% YoY |
| Cash position | ₹2,426 cr |
| One-off labour cost impact | ₹11.8 cr, included in employee expenses |
| General medicines revenue share | >75%–78% of topline |
| Pediatric vaccines growth | +11% YoY, led by Boostrix, Varilrix, Havrix growing double digits |
| Shingrix annual value | ₹70–75 cr on a calendar year basis; ~100,000 doses sold in CY2025 |
| Nucala patient run-rate | ~100 patients per month in Q3 |
| Digital touch points | ~0.4 cr for the quarter, including face-to-face interactions |
| Total employees | ~3,000; sales field force of ~2,000 |
| Portfolio under NLEM price control | 35%–38% of overall portfolio |
| Oncology key account specialists | ~25, covering 850–1,000 oncologists |